Time for gender mainstreaming in editorial policies

Journal of the International AIDS Society

Volumn 14, Issue 1, 2011, Pages

  Heidari, Shirin ^a   Eckert, Mirjam J ^a   Kippax, Susan ^b   Karim, Quarraisha Abdool ^c,d   Sow, Papa Salif ^e   Wainberg, Mark A ^f  

^a UNAIDS   (Switzerland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d Columbia University ^*  (United States)

^e UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; EDITOR; HEALTH HAZARD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEADERSHIP; MENSTRUAL CYCLE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; RESEARCH; SCIENTIFIC LITERATURE; SEX DIFFERENCE; STAGING; STANDARD; EDITORIAL; FEMALE; GENDER IDENTITY; MALE;

EDITORIAL POLICIES; FEMALE; GENDER IDENTITY; HIV INFECTIONS; HUMANS; MALE; PUBLISHING; SEX FACTORS;

EID: 79952334672     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-14-11     Document Type: Article

References (19)

1. UNAIDS, Global Report http://www.unaids.org/globalreport/Global-report. htm
2. HIV infection of the genital mucosa in women. F Hladik TJ Hope, Curr HIV/AIDS Rep 2009 6 20 28 10.1007/s11904-009-0004-1 19149993
3. Clinical care issues for women living with HIV and AIDS in the United States. R Marlink H Kao E Hsieh, AIDS Res Hum Retroviruses 2001 17 1 33 10.1089/088922201750056753 11177380 (Pubitemid 32096423)
4. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. TR Sterling D Vlahov J Astemborski DR Hoover JB Margolick TC Quinn, N Engl J Med 2001 344 720 725 10.1056/NEJM200103083441003 11236775 (Pubitemid 32204989)
5. Gender difference in HIV RNA levels: a meta-analysis of published studies. S Napravnik C Poole JC Thomas JJ Eron Jr, J Acquir Immune Defic Syndr 2002 31 11 19 12352145
6. Do gender differences in CD4 cell counts matter? M Prins JR Robertson RP Brettle IH Aguado B Broers F Boufassa DJ Goldberg R Zangerle RA Coutinho A van den Hoek, AIDS 1999 13 2361 2364 10.1097/00002030-199912030-00007 10597777
7. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. B Castelnuovo A Kiragga MR Kamya Y Manabe, J Acquir Immune Defic Syndr 2011 56 59 63 10.1097/QAI.0b013e3181f5bd03 20861741
8. Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. OC Umeh JS Currier, Expert Opin Drug Metab Toxicol 2006 2 273 283 10.1517/17425255.2.2.273 16866613 (Pubitemid 46372369)
9. Gender-specific considerations in the antiretroviral management of HIV-infected women. RA Clark KE Squires, Expert Rev Anti Infect Ther 2005 3 213 227 10.1586/14787210.3.2.213 15918779 (Pubitemid 40590327)
10. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. D Burger I van der Heiden C la Porte M van der Ende P Groeneveld C Richter P Koopmans F Kroon H Sprenger J Lindemans P Schenk R van Schaik, Br J Clin Pharmacol 2006 61 148 154 10.1111/j.1365-2125.2005.02536. x 16433869 (Pubitemid 43382608)
11. Boehringer Ingelheim, Clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with VIRAMUNE (nevirapine) [Letter to healthcare professionals] Ridgefield: Boehringer Ingelheim 2004
12. HIV/AIDS. Gender inequities must be addressed in HIV prevention. R Jewkes, Science 2010 329 145 147 10.1126/science.1193794 20616253
13. Gender and sexuality: emerging perspectives from the heterosexual epidemic in South Africa and implications for HIV risk and prevention. R Jewkes R Morrell, J Int AIDS Soc 2010 13 6 20181124
14. Inclusion of women in clinical trials. JA Berlin SS Ellenberg, BMC Med 2009 7 56 10.1186/1741-7015-7-56 19818115
15. Increasing participation of women in early phase clinical trials approved by the FDA. E Pinnow P Sharma A Parekh N Gevorkian K Uhl, Womens Health Issues 2009 19 89 93 10.1016/j.whi.2008.09.009 19272558
16. Adherence to federal guidelines for reporting of sex and race/ethnicity in clinical trials. SE Geller MG Adams M Carnes, J Womens Health 2006 15 1123 1131 10.1089/jwh.2006.15.1123 (Pubitemid 46157484)
17. UNAIDS, UNAIDS Executive summary and recommendations from the UNAIDS/GCWA/ICRW/Tibotec expert group consultation on 'Making HIV Trials Work for Women and Adolescent Girls' Geneva: UNAIDS 2007
18. Consensus Statement. ASKING THE RIGHT QUESTIONS: Advancing an HIV Research Agenda for Women and Children Geneva: International AIDS Society 2010
19. Putting gender on the agenda [Editorial]. Nature 2010 465 665